聚合变应原治疗支气管哮喘临床与实验  

CLINICAL AND EXPERIMENTAL STUDIES OF POLYMERIZED ALLERGEN FOR IMMUNOTHERAPY OF BRONCHIAL ASTHMA

作　　者：陈耀球 刘启良[1] 陈升汶 李锦梅[1] 黄志清[1] 

机构地区：[1]中山医科大学孙逸仙纪念医院呼吸内科

出　　处：《中山医科大学学报》1990年第3期69-72,共4页Academic Journal of Sun Yat-sen University of Medical Sciences

摘　　要：用戊二醛使野苋菜花粉变应原聚合,再用凝胶层析法将大分子聚合变应原析出。免疫学实验表明该聚合变应原免疫原性不变而变应原性减低。28例支气管哮喘的临床对照研究表明,聚合变应原免疫治疗起效快,疗效好,可能减低气道的非特异反应性,未发现全身副反应。Twenty-eight patients with bronchial asthma were recruited for a study to evaluate the efficacy of immunotherapy with polymerized pollen allergen of Amaranthus Spinosus Linn. The patients were divided into three groups. The clinical history, results of skin test to allergens and bronchial provocation test were all similar between three groups. Eleven patients (group Ⅰ) were treated with 13 weekly injections of 730μg polymerized allergen. Group Ⅱ patients were treated with 13 weekly injection of ordinary allergen with total doses of 35μg and group Ⅲ patients received routine treatment without imrau-notherapy. Before and 13 weeks after treatment symptom scores were recorded, bronchial responsiveness to ultrasonicallp nebulized distilled water was measured. No systematic side effect occurred in group Ⅰ despite the high dosage used. Symptom scores of group Ⅰ (6.5 +2.8 were significantlp lower than those of group Ⅱ (9.9+ 2.3. P<0.05) and group Ⅲ (11.4+3.9, P<0.05)- There was significant increase in mean water PD20-FEV, in group Ⅰ (2.9ml vs 7.76ml, P<0.05)- No significant changes in PD20-FEVj were found in group Ⅱ and group Ⅲ. The results indicate that desensitization therapy with polymerized allergen is as safe as but more effective than ordinary allergen as demonstrated by decrease in both symptom score and nonspecific bronchial hyperreactivity.

关 键 词：聚合变应原 支气管哮喘 免疫疗法 

分 类 号：R562.250.5[医药卫生—呼吸系统]